Toshie Kanayasu-Toyoda
Overview
Explore the profile of Toshie Kanayasu-Toyoda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
445
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayashi K, Sano M, Kanayasu-Toyoda T, Morita Y, Yamaguchi T, Ohya K, et al.
PLoS One
. 2025 Jan;
19(12):e0316203.
PMID: 39775542
Pyrogens cause shock symptoms when released into the bloodstream. They are classified into two main categories: endotoxins (lipopolysaccharides [LPS]) and non-endotoxin pyrogens. The monocyte activation test (MAT) is an in...
2.
Kanayasu-Toyoda T, Ishii-Watabe A, Kikuchi Y, Kitagawa H, Suzuki H, Tamura H, et al.
J Cell Physiol
. 2017 Jul;
233(2):1700-1711.
PMID: 28681912
Cell therapy using endothelial progenitor cells (EPCs) is a promising strategy for the treatment of ischemic diseases. Two types of EPCs have been identified: early EPCs and late EPCs. Late...
3.
Kanayasu-Toyoda T, Tanaka T, Kikuchi Y, Uchida E, Matsuyama A, Yamaguchi T
Stem Cells
. 2016 Jan;
34(5):1251-62.
PMID: 26824798
To develop cell therapies for ischemic diseases, endothelial progenitor cells (EPCs) have been expected to play a pivotal role in vascular regeneration. It is desirable to use a molecular marker...
4.
Kanayasu-Toyoda T, Tanaka T, Ishii-Watabe A, Kitagawa H, Matsuyama A, Uchida E, et al.
J Cell Physiol
. 2015 Mar;
230(11):2763-75.
PMID: 25820539
Since the introduction of angiogenic cell therapy using early endothelial progenitor cells (EPCs), myeloid angiogenic cells (MACs) have been expected to be useful in treating ischemic diseases. In order to...
5.
Yamaguchi T, Kanayasu-Toyoda T, Uchida E
Biol Pharm Bull
. 2013 Feb;
36(2):176-81.
PMID: 23370348
Cell therapies for severe ischemic diseases such as limb ischemia, acute myocardial infarction, and cerebral ischemia have been developed through in vitro and in vivo animal and clinical studies. Active...
6.
Nishimura K, Sano M, Ohtaka M, Furuta B, Umemura Y, Nakajima Y, et al.
J Biol Chem
. 2010 Dec;
286(6):4760-71.
PMID: 21138846
The ectopic expression of transcription factors can reprogram differentiated tissue cells into induced pluripotent stem cells. However, this is a slow and inefficient process, depending on the simultaneous delivery of...
7.
Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al.
J Immunol
. 2010 Jan;
184(4):1968-76.
PMID: 20083659
The neonatal FcR (FcRn) binds to the Fc domain of IgG at acidic pH in the endosome and protects IgG from degradation, thereby contributing to the long serum half-life of...
8.
Mukai N, Akahori T, Komaki M, Li Q, Kanayasu-Toyoda T, Ishii-Watabe A, et al.
Exp Cell Res
. 2007 Dec;
314(3):430-40.
PMID: 18083163
The identification of circulating endothelial progenitor cells (EPCs) has revolutionized approaches to cell-based therapy for injured and ischemic tissues. However, the mechanisms by which EPCs promote the formation of new...
9.
Kanayasu-Toyoda T, Ishii-Watabe A, Suzuki T, Oshizawa T, Yamaguchi T
J Biol Chem
. 2007 Sep;
282(46):33507-33514.
PMID: 17827152
We previously reported that CD31(bright) cells, which were sorted from cultured AC133(+) cells of adult peripheral blood cells, differentiated more efficiently into endothelial cells than CD31(+) cells or CD31(-) cells,...
10.
Ishii-Watabe A, Kanayasu-Toyoda T, Suzuki T, Kobayashi T, Yamaguchi T, Kawanishi T
Biologicals
. 2007 Feb;
35(4):247-57.
PMID: 17321146
To improve the safety of cellular therapy products, it is necessary to establish a serum-free cell culture method that can exclude animal-derived materials in order to avoid contamination with transmissible...